Newzenpharma Announces Breakthrough in Prostate Cancer Treatment with Newzen-138

Princeton, NJ – Newzenpharma, a pioneering biopharmaceutical company at the forefront of cancer research and drug development, is proud to announce a revolutionary breakthrough in the treatment of prostate cancer. Newzen-138, the company’s flagship product, has demonstrated remarkable efficacy in inhibiting prostate cancer cell proliferation by precisely targeting DNA repair mechanisms. This new approach represents a significant advancement in cancer therapy, with the potential to transform the landscape of prostate cancer treatment.
Innovative Mechanism: Targeting DNA Repair for Precise Cancer Treatment

Newzen-138 employs an innovative strategy that disrupts the Base Excision Repair (BER) pathway, a crucial mechanism cancer cells rely on to repair damaged DNA and maintain their survival. By selectively inhibiting key enzymes within the BER pathway—specifically DNA polymerase beta (pol β) and DNA Ligase I (LIG I)—Newzen-138 effectively prevents cancer cells from repairing the DNA damage that occurs during replication and treatment. This results in a dramatic slowdown in tumor growth and metastasis.

What sets Newzen-138 apart is its ability to selectively target cancerous cells while leaving healthy, nonmalignant cells unaffected. Unlike traditional chemotherapy, which often damages healthy cells and leads to severe side effects, Newzen-138’s precision targeting ensures minimal harm to normal tissues. This represents a significant leap forward in cancer therapy, offering patients a more tolerable treatment option with reduced risk of debilitating side effects.
Demonstrated Efficacy in Preclinical Studies

Newzen-138 has been rigorously tested in preclinical models, showing impressive results in prostate cancer cell lines. In androgen-dependent prostate cancer cells, Newzen-138 significantly inhibited cell proliferation in an androgen-depleted environment—an environment often encountered in advanced prostate cancer cases. Importantly, these effects were achieved without impacting nonmalignant prostate cells, underscoring the drug’s selective action against cancerous tissues.

In addition to its impact on androgen-dependent prostate cancer, Newzen-138 is currently undergoing further investigation in androgen-independent cancer models. Preliminary studies suggest that it may enhance the efficacy of castration-resistant prostate cancer treatments, offering hope to patients with advanced forms of the disease.
Minimizing Side Effects: A New Era of Cancer Treatment

One of the most compelling aspects of Newzen-138 is its ability to provide effective cancer treatment without the common and often debilitating side effects associated with conventional chemotherapy. Patients undergoing traditional chemotherapy frequently experience a range of side effects, including nausea, fatigue, hair loss, and weakened immune function, as healthy cells are indiscriminately targeted alongside cancerous ones. Newzen-138’s targeted approach minimizes these risks, allowing patients to maintain a higher quality of life during treatment.

“Newzen-138 represents a paradigm shift in how we approach cancer therapy,” said Vishwas Bhatia, founder of Newzenpharma and a seasoned expert in drug development. “By targeting the specific DNA repair mechanisms that cancer cells rely on to survive and thrive, we are able to attack the root cause of tumor growth without causing unnecessary harm to healthy cells. This marks a new era in cancer treatment—one that prioritizes both efficacy and patient well-being.”
Potential for Expansion Beyond Prostate Cancer

While Newzen-138’s current focus is on prostate cancer, the technology behind the drug holds great promise for expansion into other cancer types. The Base Excision Repair (BER) pathway is a fundamental mechanism used by various cancers to repair DNA damage, and Newzen-138’s ability to disrupt this process could be applied to other malignancies.

In addition, ongoing research is exploring the potential of Newzen-138 in treating neurodegenerative disorders. As these diseases also involve impaired DNA repair and cellular dysfunction, the selective inhibition of BER enzymes could offer new therapeutic avenues for conditions such as Alzheimer’s, Parkinson’s, and other degenerative diseases.
Market Potential and Global Impact

The global prostate cancer market is poised for significant growth, with estimates projecting a market value of US $176.43 billion by 2033, with chemotherapy alone accounting for more than 12% of the market. Newzenpharma is positioned to capture a substantial share of this rapidly expanding market, particularly as demand increases for more effective, less toxic treatment options. Newzen-138’s ability to offer precision treatment with fewer side effects positions it as a leading candidate for addressing this growing medical need.

Beyond its commercial potential, Newzen-138 holds the promise of improving the lives of millions of patients worldwide. Prostate cancer is one of the most common cancers among men, with nearly 1.4 million new cases diagnosed globally each year. By providing a more effective, patient-friendly treatment option, Newzen-138 has the potential to reduce the burden of this disease and offer new hope to those affected.
Backed by Scientific Expertise and Rigorous Validation

Newzen-138’s development is backed by a team of experts in oncology, molecular biology, and pharmaceutical research. Newzenpharma has assembled a world-class advisory board of researchers, physicians, and industry leaders to guide the clinical and commercial development of Newzen-138.

The technology behind Newzen-138 has undergone rigorous validation through a published study, which demonstrates its efficacy and safety. The company is prepared to share these data and additional sensitive details with interested parties as it moves towards clinical trials.

Newzenpharma has also collaborated with Florida International University (FIU) and consulted with key opinion leaders (KOLs) in the field of oncology to ensure the highest standards of scientific rigor and innovation are maintained throughout the drug’s development.
Investment Opportunities and Commercialization Strategy

Newzenpharma is actively seeking strategic partnerships and investment to expedite the commercialization of Newzen-138. With a pre-money valuation of $500 million, the company is currently raising funds through a priced equity round, with minimum investments set at $5 million and maximum investments at $15 million.

“We are confident that Newzen-138 has the potential to not only disrupt the prostate cancer treatment market but also to redefine how we approach cancer therapy as a whole,” said Bhatia. “With the right partners and resources, we can accelerate the path to market and bring this groundbreaking treatment to patients who desperately need it.”
About Newzenpharma

Newzenpharma is a biopharmaceutical company dedicated to developing cutting-edge therapies for cancer and other serious diseases. The company leverages innovative science to create novel drugs that target the underlying mechanisms of disease, with a focus on precision medicine and patient-centered care. Newzenpharma is committed to advancing global health by providing safe, effective, and accessible treatment options for patients around the world.

For more information, please visit [www.newzenpharma.com] or contact:

Media Contact: Vishwas Bhatia, CEO, [email protected], 646-270-6330

Investor Contact: Vishwas Bhatia, CEO, [email protected], 646-270-6330